IE43611B1 - Antihypertonic agent - Google Patents

Antihypertonic agent

Info

Publication number: IE43611B1
Authority: IE; Ireland
Prior art keywords: etozolin; antihypertonic; acid; dosage; antihypertensive
Prior art date: 1975-07-18

Application number

IE1580/76A

Other languages

English (en)

Other versions

IE43611L (en

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-07-18

Filing date

1976-07-16

Publication date

1981-04-08

1976-07-16 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1977-01-18 Publication of IE43611L publication Critical patent/IE43611L/xx

1981-04-08 Publication of IE43611B1 publication Critical patent/IE43611B1/en

Links

239000002220 antihypertensive agent Substances 0.000 title claims abstract description 12
229960004514 etozolin Drugs 0.000 claims description 28
ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 9
239000002775 capsule Substances 0.000 claims description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
239000008298 dragée Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
239000002934 diuretic Substances 0.000 description 18
230000003276 anti-hypertensive effect Effects 0.000 description 16
229940030606 diuretics Drugs 0.000 description 9
230000001882 diuretic effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 6
239000003792 electrolyte Substances 0.000 description 6
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
229960003883 furosemide Drugs 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000001828 Gelatine Substances 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000029142 excretion Effects 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
-1 2 - ethoxycarbonyl - methylene Chemical group 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229960004042 diazoxide Drugs 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000203 mixture Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000009955 peripheral mechanism Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IE1580/76A 1975-07-18 1976-07-16 Antihypertonic agent IE43611B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2532180A DE2532180C2 (de)	1975-07-18	1975-07-18	Verwendung von Etozolin bei der Bekämpfung der Hypertonie

Publications (2)

Publication Number	Publication Date
IE43611L IE43611L (en)	1977-01-18
IE43611B1 true IE43611B1 (en)	1981-04-08

Family

ID=5951852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE1580/76A IE43611B1 (en)	1975-07-18	1976-07-16	Antihypertonic agent

Country Status (11)

Country	Link
AU (1)	AU503445B2 (fr)
BE (1)	BE844210A (fr)
CA (1)	CA1060344A (fr)
DD (1)	DD126756A5 (fr)
DE (1)	DE2532180C2 (fr)
GB (1)	GB1550393A (fr)
GR (1)	GR61353B (fr)
IE (1)	IE43611B1 (fr)
LU (1)	LU75396A1 (fr)
PH (1)	PH13059A (fr)
ZA (1)	ZA763981B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU531659B2 (en) *	1979-03-22	1983-09-01	Goedecke Aktiengesellschaft	(+)-(3-methyl-4-oxo - 5n-piperidinothiazolidin-2-ylidene) acetic acid esters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3072653A (en) *	1961-03-06	1963-01-08	Warner Lamber Pharmaceutical C	5-amino derivatives of 4-thiazolidinones and process therefor

1975
- 1975-07-18 DE DE2532180A patent/DE2532180C2/de not_active Expired
1976
- 1976-07-05 ZA ZA763981A patent/ZA763981B/xx unknown
- 1976-07-13 GR GR51250A patent/GR61353B/el unknown
- 1976-07-14 GB GB29336/76A patent/GB1550393A/en not_active Expired
- 1976-07-16 DD DD193930A patent/DD126756A5/xx unknown
- 1976-07-16 PH PH18693A patent/PH13059A/en unknown
- 1976-07-16 BE BE168970A patent/BE844210A/fr not_active IP Right Cessation
- 1976-07-16 AU AU15959/76A patent/AU503445B2/en not_active Expired
- 1976-07-16 CA CA257,101A patent/CA1060344A/fr not_active Expired
- 1976-07-16 LU LU75396A patent/LU75396A1/xx unknown
- 1976-07-16 IE IE1580/76A patent/IE43611B1/en unknown

Also Published As

Publication number	Publication date
AU503445B2 (en)	1979-09-06
GR61353B (en)	1978-10-26
PH13059A (en)	1979-11-21
DE2532180C2 (de)	1986-12-18
ZA763981B (en)	1977-05-25
CA1060344A (fr)	1979-08-14
DE2532180A1 (de)	1977-02-10
LU75396A1 (fr)	1977-02-28
IE43611L (en)	1977-01-18
GB1550393A (en)	1979-08-15
AU1595976A (en)	1978-01-19
BE844210A (fr)	1976-11-16
DD126756A5 (fr)	1977-08-10

Publication	Publication Date	Title
DE69623634T2 (de)	2003-05-22	Pharmazeutische zusammensetzung von l-dopa ethyl ester
US5980942A (en)	1999-11-09	Zero-order sustained release matrix tablet formulations of carbamazepine
US4766117A (en)	1988-08-23	Antiinflammatory compositions and methods
EP0399051B1 (fr)	1994-05-11	Agent anti-inflammatoire polyvalent
IE42793B1 (en)	1980-10-22	Preparation for treatment of colitis
DE3517820C2 (fr)	1992-07-30
US4428951A (en)	1984-01-31	Long acting pharmaceutical composition
JP3982889B2 (ja)	2007-09-26	イブプロフェン含有医薬製剤
CN108992456A (zh)	2018-12-14	含有香叶木苷硫酸酯衍生物的药物组合物及其应用
JPH0140009B2 (fr)	1989-08-24
US4564625A (en)	1986-01-14	Binary compositions of penbutolol and furosemide or piretanide
CH667592A5 (de)	1988-10-31	9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen.
US4515802A (en)	1985-05-07	Analgesic preparations
AU756338B2 (en)	2003-01-09	Stabile compositions comprising levosimendan and alginic acid
CA1124647A (fr)	1982-06-01	Potentialisation d'un analgesique
US3729563A (en)	1973-04-24	Method of treating movement disorders
CA1060344A (fr)	1979-08-14	Agent antihypertonique
JPH0152366B2 (fr)	1989-11-08
JPH0656677A (ja)	1994-03-01	制酸剤組成物
JPS6067425A (ja)	1985-04-17	制癌剤
US4061747A (en)	1977-12-06	Antidepressant composition
US3993778A (en)	1976-11-23	Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
US3969508A (en)	1976-07-13	Lowering the concentration of plasma triglycerides
CA1249521A (fr)	1989-01-31	Composes antiinflammatoires et methode de traitement
GB2135884A (en)	1984-09-12	Analgesic preparations containing tizanidine and paracetamol